GIS

The structured XBRL table (FY2025) paints a mature but sturdy franchise: $19.5B revenue, 17.0% operating margin, 11.8% net margin, 24.9% ROE, and $4.10 diluted EPS for a headline 9.2x P/E and 1.1x P/S. Taken alone, that screens as classic deep-value staple. But the 10-K narrative for the just-closed FY2026 tells a materially worse story that overrides the trailing snapshot: net sales fell 5% to $18.4B (-2% organic), GAAP operating profit cratered 73% to $886M (an impairment-driven collapse), and the company posted a diluted LOSS per share of $(0.16). Even stripping charges out, adjusted operating profit fell 16% constant-currency and adjusted EPS fell 16% to $3.55 — so on a clean basis the shares trade near 10.6x, not 9.2x. This is a franchise whose earnings power is actively eroding, not merely flat.

The cause is structural, not one-off. Management admits it failed its top priority — returning North America Retail to volume growth — as organic pound volume fell 1% amid weak consumer sentiment and category slowdown, and Pet growth was undercut by retailer destocking. The Risk Factors flag the real threats plainly: intensifying private-label/generic competition, a consolidating retail base (Walmart alone is 22% of consolidated sales and 31% of North America Retail — dangerous customer concentration), commodity/tariff cost volatility, and, notably, the explicit call-out of weight-loss (GLP-1) drugs reshaping eating habits. Against a five-year revenue band that has gone essentially nowhere ($18.1B→$20.1B→$19.5B) and net income that peaked at $2.71B in FY2022 and has fallen every year since to $2.30B, the trend line is down.